Stories from Staines-upon-Thames

26.03.2019 – 15:29

Mallinckrodt Plc.
Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation

Staines-Upon-Thames, England (ots/PRNewswire) - EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...

more
20.03.2018 – 09:02

Mallinckrodt Plc.
Mallinckrodt Announces First Investigator Award for Pioneering Efforts in ECP Immunomodulation

Staines-Upon-Thames, England (ots/PRNewswire) - EUR50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the inaugural recipient of its Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award. The winning entry was submitted by ...

more
30.08.2011 – 09:04

Astellas Pharma Europe Limited
Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe

Staines, England (ots/PRNewswire) - Astellas Pharma Inc. [http://www.astellas.com/en/corporate ] today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency. ...

more
20.05.2011 – 16:37

Astellas Pharma Europe Limited
Astellas Receives Positive Opinion From CHMP for European Approval of VIBATIV(TM) for Nosocomial Pneumonia Caused by MRSA

Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the ...

more

1